| Company/Division name | Arrowhead Pharmaceuticals, Inc. |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 250 |
| Year reshoring announced: | 2020 |
| Year reshoring implemented or to be implemented: | 2023 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 200 |
| City reshored to: | Verona |
| State(s) reshored to: | WI |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | RNAi medicines |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies |
